Search

Displaying results 1451 - 1460 of 8412 in total
  1. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype. … Inflammation-predominant asthma, which is chatacterized by eosinophilic infiltration of airway mucosa and elevated levels of eosinophils in the blood, sputum and BAL fluid, is associated with an increased

  2. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    [A264344] In 2014, it was withdrawn voluntarily from the market due to manufacturing issues; however, the biologics license application (BLA) for denileukin diftitox was resubmitted, and it was approved … Denileukin diftitox is an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met<sub>1</sub>-Thr<sub

  3. Drug

    Icodextrin

    go.drugbank.com/drugs/DB00702
    ApprovedInvestigational

    Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers.

    Mixtures: SOLUCIÓN DP PISA DXT
  4. Drug

    Clonidine

    go.drugbank.com/drugs/DB00575
    ApprovedInvestigational

    Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Mar-clonidine, Nu-clonidine Tab 0.2mg
  5. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart.

    Mixtures: ZIVATA-DUO, ASOFLON-DUOCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … [L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  7. Drug

    Satricabtagene autoleucel

    go.drugbank.com/drugs/DB18288
    Investigational

    Satricabtagene autoleucel is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).

  8. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Target

    Aldo-keto reductase family

    go.drugbank.com/bio_entities/BE0009802
    EnzymeHumans

    Catalyzes the reduction of estrone into 17beta-estradiol but with low efficiency (PubMed:14672942). … Can form 17beta-hydroxysteroids such as testosterone and estradiol albeit with lower efficiency when compared to AKR1C3 (PubMed:10998348).

    Synonyms: Estradiol 17-beta-dehydrogenase AKR1B15
  10. Drug

    Buspirone

    go.drugbank.com/drugs/DB00490
    ApprovedInvestigational

    Due to these characteristics, buspirone been termed 'anxioselective'.[A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®.

    Categories: Dopamine D2 Receptor Antagonists, P-glycoprotein inhibitors